Sherry Rohekar, BSc., MD, FRCPC, MSc - Targeting the IL-17 Pathway in PsA and axSpA: Precision Strategies for Patient-Centered Care

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Iran's President Addresses the UN General Assembly 3 min · 23 Sep 2026 · Fox News Hourly Update

Matheson on Guerrero Jr.'s contract comments, his season performance and the optics of the statement 10 min · 23 Sep 2026 · OverDrive

Tension grows in the housing market 26 min · 23 Sep 2026 · Marketplace

Vladdy's Controversial Contract Comments 24 min · 23 Sep 2026 · Blair & Barker

Dreger on Babcock's role with the Oilers, Hiller leading the Maple Leafs and Fantilli's contract value 19 min · 23 Sep 2026 · OverDrive

Evening Wire: President Xi Arrives In Washington & Category 5 Hurricane Approaches Mexico | 9.23.26 10 min · 23 Sep 2026 · Morning Wire

Report any issue

Source

Recorded17 Dec 2025

Publisherc.answersincme.com ↗

Handlerec:14844501

Show notes

Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in